Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia

This study tests a 3-drug combination — chidamide, venetoclax, and azacitidine — for people newly diagnosed with acute myeloid leukemia (AML), a fast-growing blood cancer, who are not healthy enough for intensive chemotherapy. **You may be eligible if...** - You are 18 or older with a new diagnosis of AML (not a certain subtype called M3) - You have not received any prior treatment for AML - You are not a candidate for intensive chemotherapy due to age (75+) or health conditions like heart disease, reduced lung function, or kidney issues - Your expected survival is at least 3 months **You may NOT be eligible if...** - You have another active cancer - You have previously taken chidamide, venetoclax, or azacitidine - Your AML is classified as low-risk - You have AML that has spread to the brain - You are pregnant or breastfeeding - You have had a serious heart event (like a heart attack) in the past year Talk to your doctor to see if this trial is right for you.